RT Journal Article
SR Electronic
T1 Expression of C5aR1 in Cutaneous Squamous Cell Carcinoma is Associated with Invasion, Metastasis and Poor Prognosis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.16.24312116
DO 10.1101/2024.08.16.24312116
A1 Heiskanen, Lauri
A1 Nissinen, Liisa
A1 Siljamäki, Elina
A1 Knuutila, Jaakko
A1 Pellinen, Teijo
A1 Kallajoki, Markku
A1 Heino, Jyrki
A1 Riihilä, Pilvi
A1 Kähäri, Veli-Matti
YR 2024
UL http://medrxiv.org/content/early/2024/08/19/2024.08.16.24312116.abstract
AB Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer, and the metastatic disease is associated with poor prognosis. We have examined the role of complement C5a receptor, C5aR1, in the progression and metastasis of cSCC. C5aR1 expression was increased in cSCC cells in 3D spheroid co-culture model in the presence of fibroblasts, and that treatment with recombinant C5a enhanced the invasion of cSCC cells. Staining for C5aR1 was detected on the surface of tumor cells at the invasive edge of human cSCC xenografts in vivo. Staining of metastatic and non-metastatic primary human cSCCs, premalignant and benign epidermal lesions and normal skin for C5aR1 with multiplex immunofluorescence and chromogenic immunohistochemistry revealed increased expression of C5aR1 on the surface of tumor cells and fibroblasts in invasive cSCCs and recessive dystrophic epidermolysis bullosa–associated cSCCs compared to cSCC in situ, actinic keratoses, seborrheic keratoses and normal skin. Increased expression of C5aR1 on the tumor cell surface and in fibroblasts was associated with metastatic risk and poor disease-specific survival of patients with primary cSCC. These findings reveal the role of C5aR1 in cSCC invasion and identify C5aR1 as a novel biomarker for metastasis risk and poor prognosis in patients with cSCC. The results also suggest that C5aR1 could be a novel therapeutic target for treatment of locally advanced and metastatic cSCC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by Sigrid Juselius Foundation, Jane and Aatos Erkko Foundation, Finnish Cancer Foundation, Cancer Foundation of the Southwest Finland, Finnish Dermatological Society, The Maud Kuistila Memorial Foundation, Ida Montin Foundation, The Finnish Medical Foundation, Finnish Cultural Foundation, Paivikki and Sakari Sohlberg Foundation and Turku University Hospital VTR grants (project number: 13336).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by The Ethics Committee of the Hospital District of Southwest Finland and Auria Biobank Scientific Steering Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data underlying this article cannot be shared publicly due to patient data protection regulations.